What changed for peptides, 2023 to 2026
In 2023 the FDA flagged BPC-157, TB-500 and other peptides as bulk substances that may present significant safety risks. In July 2026 an FDA advisory committee recommended six of them for compounding, and on 28 October 2026 HHS issued an interim policy letting licensed pharmacists and physicians compound them on prescription. The human evidence for those six barely changed over the same period.
A sourced timeline of U.S. peptide regulation, from the FDA's 2023 safety flags to the October 2026 HHS interim compounding policy.
The rules moved much faster than the evidence did.
Key takeaways
- Access widened in 2026; the evidence base did not.
- FDA scientists objected to the October 2026 policy on safety grounds, according to the Associated Press.
- GLP-1 shortages ended in 2024-2025, closing the temporary window for compounded copies.
- Every event below links to its source.
Why access and evidence diverged
Regulators decide who may make and supply a product. Evidence comes only from trials. In 2026 the first decision moved quickly while the second barely moved: the first randomized human trial of BPC-157 only began recruiting in February 2026. Reading a change in access as a change in evidence is the most common mistake in coverage of this story.
What to watch next
Formal FDA rulemaking on the 503A bulk substances list, any revision or withdrawal of the interim policy, and results from the first human trials. This page and the status tracker will be updated as each happens.
Frequently asked questions
Is the interim policy permanent?
No. HHS describes it as interim and says it may revise or withdraw it in whole or in part if safety signals or product quality issues arise. It is a stopgap while the FDA completes rulemaking.
Related on Beiing
- Peptide status tracker - Where things stand today.
- Research and experimental peptides - Reading the 2026 shift carefully.
- How Beiing rates peptide evidence - The five evidence levels used across this section.
- Peptides & Human Biology - The hub for every page in this section.
- Editorial Standards - How our content is researched and reviewed.
Sources
- Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (Federal Register document 2026-22192, docket HHS-OASH-2026-0496) - U.S. Department of Health and Human Services, via the Federal Register
- AP report: FDA scientists opposed the move to ease peptide access - Associated Press, via PBS NewsHour
- HHS enforcement discretion policy allows peptide compounding (28 October 2026) - STAT
- Peptides at a crossroads: what wellness providers need to know (16 October 2026) - Holland & Knight
- Use of untested 'Wolverine' peptide on the rise, study finds (September 2026) - Reuters, via CTV News
- Peptides (4 March 2026) - The Dose
- BPC-157 for acute hamstring strain, NCT07437547 - ClinicalTrials.gov, U.S. National Library of Medicine
- FDA winds down GLP-1 compounding policies (1 April 2025) - TechTarget Pharma Life Sciences
Written by Beiing Editorial Team · Editorially reviewed by Research & Regulatory Review Desk · Published · Last reviewed . Editorial and research review by Beiing writers and researchers. This is not medical or clinical review, and no clinician signs off on our content.
Educational content only - not medical advice. In a crisis, call or text 988 (US) or your local emergency number. See crisis resources.